SI2968301T1 - Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C - Google Patents

Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C

Info

Publication number: SI2968301T1
Authority: SI; Slovenia
Prior art keywords: antivirals; combination; treating hepatitis; hepatitis; treating
Prior art date: 2013-03-14

Application number

SI201430265A

Other languages

English (en)

Inventor

Barry M. Bernstein

Sandeep Dutta

Wei Liu

Thomas J. Podsadecki

Andrew L. Campbell

Rajeev M. Menon

Chih-Wei Lin

Tianli Wang

Walid M. Awni

Sven Mensing

Original Assignee

Abb Vie Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-14

Filing date

2014-03-14

Publication date

2017-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2968301(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-14 Application filed by Abb Vie Inc. filed Critical Abb Vie Inc.

2017-07-31 Publication of SI2968301T1 publication Critical patent/SI2968301T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SI201430265A 2013-03-14 2014-03-14 Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C SI2968301T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361783376P	2013-03-14	2013-03-14
PCT/US2014/027423 WO2014152514A1 (en)	2013-03-14	2014-03-14	Combination of two antivirals for treating hepatitis c
EP14719977.2A EP2968301B1 (en)	2013-03-14	2014-03-14	Combination of two antivirals for treating hepatitis c

Publications (1)

Publication Number	Publication Date
SI2968301T1 true SI2968301T1 (sl)	2017-07-31

Family

ID=50588882

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201431674T SI3213750T1 (sl)	2013-03-14	2014-03-14	Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C
SI201430265A SI2968301T1 (sl)	2013-03-14	2014-03-14	Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI201431674T SI3213750T1 (sl)	2013-03-14	2014-03-14	Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C

Country Status (26)

Country	Link
US (1)	US20140275099A1 (sl)
EP (3)	EP2968301B1 (sl)
JP (4)	JP6441303B2 (sl)
KR (2)	KR102210935B1 (sl)
CN (2)	CN108159393A (sl)
AU (2)	AU2014239563B2 (sl)
BR (1)	BR112015023017B1 (sl)
CA (1)	CA2901810C (sl)
CY (2)	CY1119025T1 (sl)
DK (2)	DK3213750T3 (sl)
EA (2)	EA201991174A1 (sl)
ES (2)	ES2824473T3 (sl)
HK (2)	HK1223817A1 (sl)
HR (2)	HRP20171036T1 (sl)
HU (2)	HUE052113T2 (sl)
IL (1)	IL240419B (sl)
LT (2)	LT3213750T (sl)
MX (2)	MX362616B (sl)
NZ (2)	NZ719137A (sl)
PL (2)	PL3213750T3 (sl)
PT (2)	PT3213750T (sl)
RS (2)	RS60881B1 (sl)
SG (2)	SG11201507364SA (sl)
SI (2)	SI3213750T1 (sl)
TW (2)	TWI642436B (sl)
WO (1)	WO2014152514A1 (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201507364SA (en)	2013-03-14	2015-10-29	Abbvie Inc	Combination of two antivirals for treating hepatitis c
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
US20150011481A1 (en) *	2013-07-02	2015-01-08	Abbvie Inc.	Methods for Treating HCV
MX2016005393A (es) *	2013-10-25	2016-08-11	Abbvie Inc	Metodos para tratar vhc.
US20150174194A1 (en) *	2013-12-19	2015-06-25	Abbvie Inc.	Methods for treating liver transplant recipients
MX2016012722A (es) *	2014-04-02	2016-12-16	Abbvie Inc	Metodos para tratar el virus de la hepatitis c.
CN112891511A (zh) *	2014-04-02	2021-06-04	艾伯维公司	治疗hcv的方法
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
MX2018000218A (es) *	2015-06-26	2018-03-08	Abbvie Inc	Composiciones farmaceuticas solidas para el tratamiento del vhc.
US20230385268A1 (en) *	2022-05-17	2023-11-30	Abbvie Inc.	Methods for Treating HCV
JP6808660B2 (ja) *	2015-07-08	2021-01-06	アッヴィ・インコーポレイテッド	Ｈｃｖを処置するための方法
CN108024964B (zh) *	2015-07-17	2022-05-03	艾伯维公司	用于治疗hcv的固体药物组合物
EP3448392A4 (en)	2016-04-28	2020-01-15	Emory University	ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
EP3515442A4 (en) *	2016-09-23	2020-05-06	AbbVie Inc.	ADJUSTMENT
JP2018131439A (ja) *	2017-02-14	2018-08-23	アッヴィ・インコーポレイテッド	Ｈｃｖを処置する方法
CA2981993A1 (en) *	2017-08-02	2019-02-02	Abbvie Inc.	Methods for treating hcv
TW202012001A (zh) *	2018-04-10	2020-04-01	美商亞堤製藥公司	C型肝炎病毒(hcv)感染硬化之患者的治療
EP3883569A1 (en)	2018-11-20	2021-09-29	Abbvie Inc.	Methods for treating acute hcv
KR102077833B1 (ko)	2018-12-10	2020-02-14	류형준	기능성 식품조성물
CN111688355B (zh)	2019-03-15	2022-04-12	精工爱普生株式会社	液体吸收体、液体吸收器以及液体喷出装置
CA3136316A1 (en) *	2019-04-08	2020-10-15	Abbvie Inc.	Solid pharmaceutical compositions for treating hcv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8937150B2 (en) *	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US9394279B2 (en) *	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
AR083052A1 (es) *	2010-09-21	2013-01-30	Enanta Pharm Inc	Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas
US8330139B2 (en)	2011-03-25	2012-12-11	Micron Technology, Inc.	Multi-level memory cell
MX2014004729A (es)	2011-10-21	2014-07-28	Abbvie Inc	Tratamiento en combinacion (por ejemplo, con abt-072 o abt-333) de agentes antivirales de accion directa para utilizarse en el tratamiento del virus de la hepatitis c.
TWI532487B (zh)	2011-10-21	2016-05-11	艾伯維有限公司	治療ｃ型肝炎病毒（ｈｃｖ）之方法
HUE046544T2 (hu) *	2012-09-18	2020-03-30	Abbvie Inc	Eljárások Hepatitis C kezelésére
SG11201507364SA (en)	2013-03-14	2015-10-29	Abbvie Inc	Combination of two antivirals for treating hepatitis c

2014
- 2014-03-14 SG SG11201507364SA patent/SG11201507364SA/en unknown
- 2014-03-14 DK DK17165207.6T patent/DK3213750T3/da active
- 2014-03-14 TW TW103109530A patent/TWI642436B/zh not_active IP Right Cessation
- 2014-03-14 KR KR1020157029549A patent/KR102210935B1/ko active IP Right Grant
- 2014-03-14 EA EA201991174A patent/EA201991174A1/ru unknown
- 2014-03-14 PT PT171652076T patent/PT3213750T/pt unknown
- 2014-03-14 CN CN201810067970.1A patent/CN108159393A/zh active Pending
- 2014-03-14 PL PL17165207T patent/PL3213750T3/pl unknown
- 2014-03-14 LT LTEP17165207.6T patent/LT3213750T/lt unknown
- 2014-03-14 CN CN201480015311.3A patent/CN105073113B/zh not_active Expired - Fee Related
- 2014-03-14 KR KR1020217002760A patent/KR20210013344A/ko active Application Filing
- 2014-03-14 JP JP2016502431A patent/JP6441303B2/ja active Active
- 2014-03-14 MX MX2015012538A patent/MX362616B/es active IP Right Grant
- 2014-03-14 PT PT147199772T patent/PT2968301T/pt unknown
- 2014-03-14 ES ES17165207T patent/ES2824473T3/es active Active
- 2014-03-14 RS RS20201198A patent/RS60881B1/sr unknown
- 2014-03-14 WO PCT/US2014/027423 patent/WO2014152514A1/en active Application Filing
- 2014-03-14 SI SI201431674T patent/SI3213750T1/sl unknown
- 2014-03-14 DK DK14719977.2T patent/DK2968301T3/en active
- 2014-03-14 NZ NZ719137A patent/NZ719137A/en unknown
- 2014-03-14 PL PL14719977T patent/PL2968301T3/pl unknown
- 2014-03-14 EP EP14719977.2A patent/EP2968301B1/en not_active Revoked
- 2014-03-14 NZ NZ631155A patent/NZ631155A/en unknown
- 2014-03-14 ES ES14719977.2T patent/ES2624980T3/es active Active
- 2014-03-14 US US14/210,870 patent/US20140275099A1/en not_active Abandoned
- 2014-03-14 TW TW107108651A patent/TWI686196B/zh not_active IP Right Cessation
- 2014-03-14 SI SI201430265A patent/SI2968301T1/sl unknown
- 2014-03-14 HU HUE17165207A patent/HUE052113T2/hu unknown
- 2014-03-14 EP EP17165207.6A patent/EP3213750B1/en active Active
- 2014-03-14 CA CA2901810A patent/CA2901810C/en active Active
- 2014-03-14 EP EP20183791.1A patent/EP3766495A1/en active Pending
- 2014-03-14 LT LTEP14719977.2T patent/LT2968301T/lt unknown
- 2014-03-14 AU AU2014239563A patent/AU2014239563B2/en active Active
- 2014-03-14 BR BR112015023017-2A patent/BR112015023017B1/pt active IP Right Grant
- 2014-03-14 HU HUE14719977A patent/HUE033010T2/en unknown
- 2014-03-14 RS RS20170672A patent/RS56202B1/sr unknown
- 2014-03-14 SG SG10201708306WA patent/SG10201708306WA/en unknown
- 2014-03-14 EA EA201591702A patent/EA033257B1/ru unknown
2015
- 2015-08-06 IL IL240419A patent/IL240419B/en active IP Right Grant
- 2015-09-11 MX MX2020005054A patent/MX2020005054A/es unknown
2016
- 2016-05-03 AU AU2016202823A patent/AU2016202823B2/en active Active
- 2016-07-20 HK HK16108631.0A patent/HK1223817A1/zh unknown
- 2016-07-20 HK HK18103210.8A patent/HK1244668A1/zh unknown
2017
- 2017-06-21 CY CY20171100653T patent/CY1119025T1/el unknown
- 2017-07-06 HR HRP20171036TT patent/HRP20171036T1/hr unknown
2018
- 2018-11-22 JP JP2018219054A patent/JP6621902B2/ja active Active
2019
- 2019-11-19 JP JP2019208502A patent/JP2020037589A/ja active Pending
2020
- 2020-10-05 CY CY20201100930T patent/CY1123387T1/el unknown
- 2020-10-05 HR HRP20201575TT patent/HRP20201575T1/hr unknown
2021
- 2021-06-07 JP JP2021094935A patent/JP2021130720A/ja active Pending

Also Published As

Publication number	Publication date
HRP20171036T1 (hr)	2017-10-06
MX362616B (es)	2019-01-28
EP2968301A1 (en)	2016-01-20
HUE033010T2 (en)	2017-11-28
AU2016202823A1 (en)	2016-05-19
LT2968301T (lt)	2017-05-25
CA2901810C (en)	2019-01-08
RS60881B1 (sr)	2020-11-30
JP6441303B2 (ja)	2018-12-19
PT3213750T (pt)	2020-10-19
SG10201708306WA (en)	2017-11-29
CA2901810A1 (en)	2014-09-25
KR20150129032A (ko)	2015-11-18
EP2968301B1 (en)	2017-04-19
JP6621902B2 (ja)	2019-12-18
IL240419A0 (en)	2015-09-24
NZ631155A (en)	2016-05-27
EA201591702A1 (ru)	2016-09-30
TW201511759A (zh)	2015-04-01
DK3213750T3 (da)	2020-10-19
TW201834656A (zh)	2018-10-01
KR102210935B1 (ko)	2021-02-02
CN105073113B (zh)	2018-01-02
IL240419B (en)	2019-03-31
SG11201507364SA (en)	2015-10-29
HK1223817A1 (zh)	2017-08-11
TWI686196B (zh)	2020-03-01
CN108159393A (zh)	2018-06-15
BR112015023017A2 (pt)	2017-07-18
ES2624980T3 (es)	2017-07-18
JP2016513695A (ja)	2016-05-16
US20140275099A1 (en)	2014-09-18
AU2014239563A1 (en)	2015-08-27
CY1123387T1 (el)	2021-12-31
KR20210013344A (ko)	2021-02-03
LT3213750T (lt)	2020-10-26
PL3213750T3 (pl)	2020-12-14
MX2020005054A (es)	2020-08-20
TWI642436B (zh)	2018-12-01
JP2020037589A (ja)	2020-03-12
AU2016202823B2 (en)	2017-11-23
MX2015012538A (es)	2016-02-10
AU2014239563B2 (en)	2016-05-05
EP3213750B1 (en)	2020-08-12
HK1244668A1 (zh)	2018-08-17
EA033257B1 (ru)	2019-09-30
JP2021130720A (ja)	2021-09-09
HRP20201575T1 (hr)	2020-12-11
SI3213750T1 (sl)	2020-11-30
PL2968301T3 (pl)	2017-09-29
EP3766495A1 (en)	2021-01-20
HUE052113T2 (hu)	2021-04-28
NZ719137A (en)	2017-11-24
BR112015023017B1 (pt)	2022-08-30
ES2824473T3 (es)	2021-05-12
JP2019048868A (ja)	2019-03-28
RS56202B1 (sr)	2017-11-30
DK2968301T3 (en)	2017-07-24
EA201991174A1 (ru)	2020-01-31
WO2014152514A1 (en)	2014-09-25
CN105073113A (zh)	2015-11-18
EP3213750A1 (en)	2017-09-06
PT2968301T (pt)	2017-07-17
CY1119025T1 (el)	2018-01-10

Publication	Publication Date	Title
HK1223817A1 (zh)	2017-08-11	用於治療丙型肝炎的兩種抗病毒劑的組合
IL278912A (en)	2021-01-31	Improved preparations for the treatment of muscular dystrophy
HK1213886A1 (zh)	2016-07-15	用於治療心血管疾病的 -哌啶- -基苯甲酰胺衍生物
HUE050485T2 (hu)	2020-12-28	Tauopathia kezelési módszerei
HK1209319A1 (en)	2016-04-01	Methods for treating hepatitis c
EP2968273A4 (en)	2016-08-31	METHOD FOR THE TREATMENT OF MUSCLE DYSTROPHIES
HK1209320A1 (en)	2016-04-01	Methods for treating hepatitis c
IL241096A0 (en)	2015-11-30	Treatment methods
GB201308466D0 (en)	2013-06-19	Improved process for treatment of minewater
GB201322764D0 (en)	2014-02-05	Treating places
GB201322778D0 (en)	2014-02-05	Method of treatment
GB201314882D0 (en)	2013-10-02	Method of treatment